Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 24, 2025 17:03 ET | Source: SciSparc Ltd

SciSparc Announces 1-for-21 Reverse Share Split

Tel Aviv, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of...
May 27, 2025 07:32 ET | Source: SciSparc Ltd

SciSparc Announces Publication of Japanese Patent Application

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
May 12, 2025 07:32 ET | Source: SciSparc Ltd

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
April 25, 2025 07:59 ET | Source: SciSparc Ltd

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
March 10, 2025 07:45 ET | Source: SciSparc Ltd

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
March 03, 2025 08:25 ET | Source: SciSparc Ltd

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc will sell its MitoCareX’s shares for $700,000 and exchange its remaining shares for common stock in N2OFF TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...
February 27, 2025 08:45 ET | Source: SciSparc Ltd

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
February 18, 2025 07:17 ET | Source: SciSparc Ltd

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
February 04, 2025 09:00 ET | Source: SciSparc Ltd

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
January 15, 2025 07:34 ET | Source: SciSparc Ltd

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares TEL AVIV, Israel, Jan. 15, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a...

Next Page keyboard_arrow_right